Compelling evidence of the therapeutic benefits of psychedelic drugs appears in multiple scientific studies. Several clinical trials are underway in the United States and worldwide to investigate the therapeutic effects of psilocybin, the active component in the fungi known colloquially as “magic mushrooms.” There is new hope for treating such debilitating disorders as depression, anxiety, post-traumatic stress disorder, anorexia, obsessive-compulsive disorder, and addiction. With more than $6.8 billion on the line by 2027, companies at the vanguard of the psychedelic therapeutic drug market could reap enormous benefits in the coming years. Some of these companies, such as Cybin Corp. (Cybin Profile), which focuses on drug development and unique delivery mechanisms, are targeting areas that have been particularly underserved in the past decade. Those areas encompass life-disrupting psychiatric and neurological conditions such as major depressive disorder (MDD), addictions, and other mental illnesses. A pioneer in the psychedelic sector, CYBIN is working toward becoming the first life sciences company to bring a psilocybin drug targeting MDD to market. A successful outcome could completely upend treatment protocols. The psychedelic space’s promise is perhaps best illustrated by the sector’s largest-ever private financing round of $80 million for Compass Pathways (NASDAQ: CMPS), the first psychedelic company to IPO on the NASDAQ. Not to be outdone, Mind Medicine Inc. (OTC: MMEDF) is following suit; the company applied for NASDAQ uplisting last month. In addition, Field Trip Health Ltd. (CSE: FTRP) started trading on the Canadian Securities Exchange (CSE) earlier this month.
To hear the NetworkNewsAudio version, visit https://nnw.fm/DIhMy
To view the full editorial, visit https://nnw.fm/azE5Y
About Cybin Corp.
Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit www.NetworkNewsAudio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.